Cao Yifan, Liu Hao, Zhang Heng, Lin Chao, Li Ruochen, Wu Songyang, Li He, He Hongyong, Zhang Weijuan, Xu Jiejie
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Oncotarget. 2017 Mar 21;8(12):20328-20339. doi: 10.18632/oncotarget.12815.
Backround: Abnormal expression of CXC chemokine receptor 1 (CXCR1) has shown the ability to promote tumor angiogensis, invasion and metastasis in several cancers. The purpose of our curret study is to discover the clinical prognostic significance of CXCR1 in resectable gastric cancer.
330 gastric cancer patients who underwent R0 gastrectomy with standard D2 lymphadenectomy at Zhongshan Hospital, Fudan University between 2007 and 2008 were enrolled. CXCR1 expression was evaluated with use of immunohistochemical staining. The relation between CXCR1 expression and clinicopathological features and postoperative prognosis was respectively inspected.
In both discovery and validation data sets, CXCR1 high expression indicated poorer overall survival (OS) in TNM II and III patients. Furthermore, multivariate analysis identified CXCR1 expression and TNM stage as two independent prognostic factors for OS. Incorporating CXCR1 expression into current TNM staging system could generate a novel clinical predictive model for gastric cancer, showing better prognostic accuracy with respect to patients' OS. More importantly, TNM II patients with higher CXCR1 expression were shown to significantly benefit from postoperative 5-fluorouracil (5-FU) based adjuvant chemotherapy (ACT).
CXCR1 in gastric cancer was identified as an independent adverse prognostic factor. Combining CXCR1 expression with current TNM staging system could lead to better risk stratification and more accurate prognosis for gastric cancer patients. High expression of CXCR1 identified a subgroup of TNM stage II gastric cancer patients who appeared to benefit from 5-FU based ACT.
背景：CXC趋化因子受体1（CXCR1）的异常表达已显示出在几种癌症中促进肿瘤血管生成、侵袭和转移的能力。我们当前研究的目的是发现CXCR1在可切除胃癌中的临床预后意义。
纳入2007年至2008年期间在复旦大学附属中山医院接受标准D2淋巴结清扫的R0胃切除术的330例胃癌患者。使用免疫组织化学染色评估CXCR1表达。分别检查CXCR1表达与临床病理特征及术后预后之间的关系。
在发现和验证数据集中，CXCR1高表达表明TNM II期和III期患者的总生存期（OS）较差。此外，多变量分析确定CXCR1表达和TNM分期是OS的两个独立预后因素。将CXCR1表达纳入当前的TNM分期系统可以生成一种新的胃癌临床预测模型，在患者OS方面显示出更好的预后准确性。更重要的是，CXCR1表达较高的TNM II期患者显示出从术后基于5-氟尿嘧啶（5-FU）的辅助化疗（ACT）中显著获益。
胃癌中的CXCR1被确定为独立的不良预后因素。将CXCR1表达与当前的TNM分期系统相结合可以导致更好的风险分层和对胃癌患者更准确的预后。CXCR1的高表达确定了一组TNM II期胃癌患者，他们似乎从基于5-FU的ACT中获益。
